WealthTrust Axiom LLC Has $219,000 Stake in Zynex, Inc. (NASDAQ:ZYXI)

WealthTrust Axiom LLC trimmed its position in Zynex, Inc. (NASDAQ:ZYXIGet Rating) by 27.9% in the first quarter, HoldingsChannel.com reports. The firm owned 35,288 shares of the company’s stock after selling 13,651 shares during the period. WealthTrust Axiom LLC’s holdings in Zynex were worth $219,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Qube Research & Technologies Ltd raised its stake in shares of Zynex by 32.8% in the first quarter. Qube Research & Technologies Ltd now owns 29,480 shares of the company’s stock valued at $184,000 after purchasing an additional 7,275 shares in the last quarter. Texas Permanent School Fund grew its position in Zynex by 12.3% in the first quarter. Texas Permanent School Fund now owns 16,054 shares of the company’s stock valued at $100,000 after acquiring an additional 1,762 shares during the period. Rice Hall James & Associates LLC grew its position in Zynex by 13.4% in the first quarter. Rice Hall James & Associates LLC now owns 64,870 shares of the company’s stock valued at $404,000 after acquiring an additional 7,645 shares during the period. New York State Common Retirement Fund grew its position in Zynex by 212.4% in the first quarter. New York State Common Retirement Fund now owns 162,311 shares of the company’s stock valued at $1,011,000 after acquiring an additional 110,361 shares during the period. Finally, Janney Montgomery Scott LLC grew its position in Zynex by 93.6% in the first quarter. Janney Montgomery Scott LLC now owns 141,916 shares of the company’s stock valued at $884,000 after acquiring an additional 68,602 shares during the period. 28.06% of the stock is currently owned by institutional investors and hedge funds.

Zynex Stock Performance

Shares of NASDAQ:ZYXI opened at $9.34 on Friday. The business’s fifty day moving average price is $7.82 and its two-hundred day moving average price is $7.09. Zynex, Inc. has a fifty-two week low of $4.97 and a fifty-two week high of $14.24. The stock has a market capitalization of $358.72 million, a price-to-earnings ratio of 18.89 and a beta of 0.76. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.75 and a quick ratio of 2.98.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating on shares of Zynex in a research report on Friday, July 29th.

About Zynex

(Get Rating)

Zynex, Inc, through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device.

Further Reading

Want to see what other hedge funds are holding ZYXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zynex, Inc. (NASDAQ:ZYXIGet Rating).

Institutional Ownership by Quarter for Zynex (NASDAQ:ZYXI)

Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.